BriaCell has added two clinical trial sites to accelerate patient enrollment. CanadianBusinessJournal

Philadelphia and Vancouver, British Columbia, February 28, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or “Company”)A clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer is conducting Phase I / IIa combination trials of Bria-IMT ™, a leading candidate for BriaCell, to screen and enroll patients with advanced breast cancer. Announced that we are recruiting two additional clinical sites. , Incyte’s checkpoint inhibitor retifane limab and its immunomodulator epacadostat. Additional clinical sites include: 1) Atlantic Health System in Morristown, NJ, and 2) Tranquil Clinical Research in Webster, Texas.

BriaCell’s clinical site works closely with Cancer Insight, LLC to manage the clinical and regulatory aspects of Phase I / IIa clinical trials in advanced breast cancer on behalf of BriaCell. The following clinical sites are currently open and are actively enrolling patients.

  • Atlantic Health System in Morristown, NJ
  • Quiet clinical and research, Webster, Texas
  • Mary Crowley Cancer Research Center, Dallas, Texas
  • St. Joseph Health-Sonoma County, Santa Rosa, CA
  • Kansas Cancer Center in Wichita, Kansas

Dr. Bill Williams, President and Chief Executive Officer of BriaCell, said: “There is an urgent need for well-tolerated and effective treatments for patients with advanced breast cancer, and these treatments are available to the leading oncologists and healthcare providers in these clinical settings. I look forward to working with others. “

Atlantic health system

Founded in 1996, the Atlantic Health System was created to provide quality, affordable and accessible care to patients in northern and central New Jersey. It has fulfilled its mission to build a healthier community and has grown into a network of over 17,000 members and 4,800 doctors. The Atlantic Health System has 400 medical care, including 7 hospitals, 300 doctor’s clinics, 16 emergency medical centers, home and hospices services, mobile health, distance care, education, research, and joint partnerships in receiving community care. We serve more than 1 million patients annually through our facility. Several clinical awards from the US News & World Report.

Quiet clinical study

With over 30 years of experience, Tranquil Clinical Research has provided new treatments for patients in Webster, Texas. The focus was on providing patients with excellence in the clinical trial process and reliable products. The facility is strategically located near the Texas Medical Center (TMC) in Houston, Texas, the world’s largest medical facility.

About BriaCell Therapeutics Corp

BriaCell is a biotechnology company focused on immuno-oncology, developing targeted and effective approaches to cancer management. For more information, please visit https: //

Safe harbor

This press release contains “forward-looking statements” that are subject to significant risks and uncertainties. All statements in this press release, except for historical facts, are forward-looking statements. The forward-looking statements contained in this press release are “anticipate,” “believe,” “contemplate,” “potential,” “estimate,” “expect,” “intend,” and “intention.” It can be identified by using words such as “seek”. “May”, “May”, “Plan”, “May”, “Predict”, “Project”, “Goal”, “Aim”, “Should” , “Do”, “will”, or these negative words or other similar expressions. However, not all forward-looking statements include these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. In addition, certain forward-looking statements are based on assumptions about future events that may not prove accurate. These and other risks and uncertainties are addressed to Canadian securities regulators and the US Securities and Exchange Commission under the heading “Risks and Uncertainties” in discussions and analyzes by our latest management. It is explained more fully under “Risks and Uncertainties” in the filings. Exchange Committee. All of these are available at in SEDAR and the following EDGAR profiles: Forward-looking statements contained in this announcement have been made as of this date and BriaCell Therapeutics Corp. is not obligated to update such information unless required by applicable law. Hmm.

Neither the Toronto Stock Exchange nor its regulatory service provider (the term is defined in the Toronto Stock Exchange policy) is responsible for the validity or accuracy of this release.

contact address

Company contact:
William V. Williams Doctor of Medicine
President and CEO

Public relations window to the media:
Jules Abraham
Public Relations Director
Core IR

Investor spokesperson:
Core IR

CBJ News Maker

BriaCell has added two clinical trial sites to accelerate patient enrollment. CanadianBusinessJournal

Source link BriaCell has added two clinical trial sites to accelerate patient enrollment. CanadianBusinessJournal

Related Articles

Back to top button